When is crossover desirable in cancer drug trials and when is it problematic?

Published 2018 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
When is crossover desirable in cancer drug trials and when is it problematic?
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 29, Issue 5, Pages 1079-1081
Publisher
Oxford University Press (OUP)
Online
2018-04-10
DOI
10.1093/annonc/mdy116

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.